ONJ in Two Dental Practice-Based Research Network Regions

被引:39
作者
Fellows, J. L. [1 ]
Rindal, D. B. [2 ]
Barasch, A. [3 ]
Gullion, C. M. [1 ]
Rush, W. [2 ]
Pihlstrom, D. J. [4 ]
Richman, J. [5 ]
机构
[1] Kaiser Permanente Ctr Hlth Res, Portland, OR 97227 USA
[2] HealthPartners Res Fdn, Minneapolis, MN USA
[3] Univ Alabama Birmingham, Dept Gen Dent Sci, Birmingham, AL USA
[4] Permanente Dent Associates, Portland, OR USA
[5] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA
基金
美国国家卫生研究院;
关键词
osteonecrosis; bisphosphonates; cohort study; Dental PBRN; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS; RISK-FACTORS; ORAL BISPHOSPHONATES; JAW; OSTEOPOROSIS; PREVENTION; GUIDELINES; SURGERY;
D O I
10.1177/0022034510387795
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The incidence of osteonecrosis of the jaw (ONJ) in the population is low, but specifics are unknown. Potential risk factors include bisphosphonate treatment, steroid treatment, osteoporosis, and head/neck radiation. This Dental Practice-Based Research Network study estimated ONJ incidence and odds ratios from bisphosphonate exposure and other risk factors using a key word search and manual chart reviews of electronic records for adults aged >= 35 yrs enrolled during 1995-2006 in two large health-care organizations. We found 16 ONJ cases among 572,606 cohort members; seven additional cases were identified through dental plan resources. Among 23 cases (0.63 per 100,000 patient years), 20 (87%) had at least one risk factor, and six (26%) had received oral bisphosphonates. Patients with oral bisphosphonates were 15.5 (CI, 6.0-38.7) more likely to have ONJ than non-exposed patients; however, the sparse number of ONJ cases limits firm conclusions and suggests that the absolute risks for ONJ from oral bisphosphonates is low.
引用
收藏
页码:433 / 438
页数:6
相关论文
共 26 条
[21]   Bisphosphonate mechanism of action [J].
Alfred A. Reszka ;
Gideon A. Rodan .
Current Rheumatology Reports, 2003, 5 (1) :65-74
[22]   Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis [J].
Rizzoli, Rene ;
Burlet, Nansa ;
Cahall, David ;
Delmas, Pierre D. ;
Eriksen, Erik Fink ;
Felsenberg, Dieter ;
Grbic, John ;
Jontell, Mats ;
Landesberg, Regina ;
Laslop, Andrea ;
Wollenhaupt, Martina ;
Papapoulos, Socrates ;
Sezer, Orhan ;
Sprafka, Michael ;
Reginster, Jean-Yves .
BONE, 2008, 42 (05) :841-847
[23]   Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer [J].
Ruggiero, Salvatore ;
Gralow, Julie ;
Marx, Robert E. ;
Hoff, Ana O. ;
Schubert, Mark M. ;
Huryn, Joseph M. ;
Toth, Bela ;
Damato, Kathryn ;
Valero, Vicente .
JOURNAL OF ONCOLOGY PRACTICE, 2006, 2 (01) :7-14
[24]   Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis [J].
Wilkinson, Gregg S. ;
Kuo, Yong-Fang ;
Freeman, Jean L. ;
Goodwin, James S. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (13) :1016-1024
[25]   Systematic review: Bisphosphonates and osteonecrosis of the jaws [J].
Woo, Sook-Bin ;
Hellstein, John W. ;
Kalmar, John R. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :753-761
[26]   Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome [J].
Yarom, N. ;
Yahalom, R. ;
Shoshani, Y. ;
Hamed, W. ;
Regev, E. ;
Elad, S. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (10) :1363-1370